Epizyme will receive up to $7.5M from the society to develop Epizyme's histone methyltransferase DOT1L (DOT1L) inhibitor for mixed lineage leukemia

The Leukemia & Lymphoma Society

U.S. / Non-Profit or Major Disease Foundation

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Epizyme Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced